|Bid||78.75 x 200|
|Ask||78.83 x 100|
|Day's Range||78.07 - 79.07|
|52 Week Range||63.68 - 95.93|
|PE Ratio (TTM)||92.99|
|Earnings Date||May 28, 2018 - Jun 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||93.12|
U.S. prosecutors were nearing their first charges against generic-drug companies in a nearly four-year-old criminal probe into a possible price-fixing, Bloomberg reported, citing people familiar with the matter. Soaring drug prices from both branded and generic drugmakers have sparked outrage and investigations in the past, with President Donald Trump last year calling it "getting away with murder". In October, Reuters reported https://www.reuters.com/article/us-usa-generics/u-s-states-allege-broad-generic-drug-price-fixing-collusion-idUSKBN1D0201 a lawsuit on the price-fixing case accused 18 companies, including Mylan and Teva Pharmaceutical, and named 15 medicines.
Eli Lilly and Co. (LLY) reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17. The company beat Wall Street analysts’ estimates for earnings-per-share (or EPS) and revenues in 1Q18 and reported EPS of $1.34 on revenues of ~$5.7 billion, compared to an estimated EPS of $1.14 on revenues of ~$5.5 billion.
LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free earnings report on Perrigo Co. PLC (NYSE: PRGO ). If you want access to this report all you need to do is sign up ...
TASE: PRGO) and its partner Dexcel Pharma Technologies, Ltd., today announced the launch of store brand Omeprazole Delayed Release Orally Disintegrating Tablets 20mg (Omeprazole ODT), an over-the-counter (OTC) medication to treat frequent heartburn. Omeprazole ODT is an FDA-approved medication, featuring MelTech™ melt-in-your-mouth technology, that dissolves in the mouth without water. This product is packaged and marketed as a store brand or retailer 'own label' brand and will provide consumers with a high-quality option for treating frequent heartburn.
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see WARNINGS, Malignant Neoplasms, Endometrial Cancer].
Perrigo Company plc (NYSE:PRGO) is trading with a trailing P/E of 98.5x, which is higher than the industry average of 22.2x. While this makes PRGO appear like a stock toRead More...
Perrigo Company (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A review of Jeffrey Smith's investing strategy and take a look inside Starboard Value's stock portfolio. Largest holdings include Perrigo Company PLC (NYSE: PRGO ), Altaba Inc (Nasdaq: AABA ), and Marvell ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding PRGO totaled $3.66 billion.
NESS ZIONA, Israel, March 26, 2018-- Sol-Gel Technologies Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...
Perrigo Company plc (NYSE:PRGO) generated a below-average return on equity of 1.94% in the past 12 months, while its industry returned 11.00%. PRGO’s results could indicate a relatively inefficient operationRead More...
TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex® DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-Release Tablets, 1200 mg/60 mg). This product will be packaged and marketed as a store brand or retailer 'own label' brand and will provide consumers with a high-quality, value alternative to Mucinex® DM Maximum Strength. The company is finalizing plans to launch Perrigo's wholly owned store brand equivalent of Mucinex® DM Maximum Strength for the 2018 cough-cold season.
TASE: PRGO) today announced that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the 2018 Barclays Global Healthcare Conference at 1:35 PM EST on Tuesday, March 13, 2018. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network.
Stock of Perrigo Co. Plc closed 4.3% higher at $82.99 on Friday, snapping a three-day losing streak for the shares, as Wall Street cheered the pharma company's earnings. Perrigo Thursday reported adjusted ...
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The top line however, drops year over year.
TASE: PRGO) today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission and released its fourth quarter and calendar year 2017 financial results. The Company will host a conference call on Friday, March 2, 2018 at 8:30AM (EST) to discuss its results. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®.
DUBLIN , March 1, 2018 /PRNewswire/ -- Fourth Quarter Realized fourth quarter 2017 GAAP ("reported") net sales of $1.3 billion , reported net income of $73 million and reported diluted earnings ...
Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.
Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, previously scheduled for Tuesday, February 27, 2018 DUBLIN , Feb. 27, 2018 /PRNewswire/ -- Select Preliminary ...
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Perrigo Co. Plc (NYSE: PRGO ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 9:30 AM Eastern Time. ...
Investors pursuing a solid, dependable stock investment can often be led to Perrigo Company plc (NYSE:PRGO), a large-cap worth US$12.43B. One reason being its ‘too big to fail’ aura whichRead More...